Market Spotlight: Acute Lymphoblastic Leukemia (ALL)

Market Spotlight: Acute Lymphoblastic Leukemia (ALL)

  • November 2020 •
  • 47 pages •
  • Report ID: 5829132 •
  • Format: PDF
This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
The analyst estimates that in 2018, there were 86,600 incident cases of acute lymphoblastic leukemia (ALL) worldwide, and expects that number to increase to 93,500 incident cases by 2027.
Approved drugs in the ALL space focus on a wide variety of targets. The majority of these therapies are administered via the intravenous route, with the remaining products being available in oral and intramuscular formulations.
Industry-sponsored drugs in active clinical development for ALL are spread evenly across Phase I and Phase II, with two drugs in Phase III.
Therapies in development for ALL focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the intravenous route, with the remainder being oral and intramuscular formulations.
High-impact upcoming events for drugs in the ALL space comprise topline Phase II trial results for Sarclisa, an expected BLA filing for Tecartus, and an estimated European supplemental approval decision for Blincyto.
The overall likelihood of approval of a Phase I hematologic asset is 9.5%, and the average probability a drug advances from Phase III is 60.3%. Drugs, on average, take 9.3 years from Phase I to approval, compared to 9.5 years in the overall oncology space.
The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for ALL have been in the early and midphases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.
The US has a substantial lead in the number of ALL clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
Clinical trial activity in the ALL space is dominated by completed trials. Novartis has the highest number of completed clinical trials for ALL, with 45 trials.
Novartis leads industry sponsors with the highest overall number of clinical trials for ALL.